What is the 13F Pro Quality Score for ARDT?

13F Pro ranks Ardent Health, Inc. (ARDT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ARDT's current score at https://13fpro.ai/research/ARDT (free sign-up required for the full ranking).

Which hedge funds own the most ARDT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ARDT include CHAI CO, Ventas,, GOLDENTREE ASSET MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ARDT as soon as new 13F filings post.

Where does 13F Pro source ARDT data?

All Ardent Health, Inc. fundamentals and ownership data come directly from SEC EDGAR. Ardent Health, Inc. files with the SEC under CIK 1756655. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ARDT in?

Ardent Health, Inc. (ARDT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ARDT research updated on 13F Pro?

ARDT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Ardent Health, Inc.(ARDT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1756655 ARDT stock profile & AI dashboard →

13F Pro Quality Score

60.7/100

Rank #834 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

69.6/100

Profitability

44.1/100

Balance Sheet

54.8/100

Earnings Quality

87.7/100

Free Cash Flow

44.0/100

Institutional Flow

34.5/100

Revenue Scale

81.6/100

Dilution Risk

94.9/100

ARDT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Ardent Health, Inc. (ARDT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARDT at 60.7/100 on a 32-signal composite quality model, placing it at rank #834 of 2,879 stocks — the top half of the AI-ranked universe. ARDT scores in the top quartile across earnings quality (87.7), revenue scale (81.6). Areas of concern include institutional flow (34.5), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Ardent Health, Inc. reports quarterly revenue of $1.6B, net income of $39.9M, an operating margin of 4.7%. Top institutional holders of ARDT by reported 13-F value include CHAI CO, Ventas,, GOLDENTREE ASSET MANAGEMENT, based on the most recent SEC filings. ARDT trades on the NYSE exchange and files with the SEC under CIK 1756655. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARDT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ardent Health, Inc. directly from SEC EDGAR. Ardent Health, Inc.'s 13F Pro composite quality score has ranged between 8 and 64 since 2025, currently 60.7 — an improving long-term trajectory across 40 quarterly and live scoring snapshots.

Revenue

Q1 2026

$1.6B

Net Income

Q1 2026

$39.9M

Free Cash Flow

Q1 2026

$-60.2M

Operating Margin

Q1 2026

4.7%

ROIC

Q1 2026

3.1%

D/E Ratio

Q1 2026

0.86

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+6.0% YoY

$6.32BFY 2025

FY22 $5.13BFY23 $5.41BFY24 $5.97BFY25 $6.32B

Net Income

-35.4% YoY

$135.8MFY 2025

FY22 $188.9MFY23 $53.9MFY24 $210.3MFY25 $135.8M

EPS (Diluted)

-39.2% YoY

$0.96FY 2025

FY22 $1.50FY23 $0.43FY24 $1.58FY25 $0.96

Total Assets

+6.7% YoY

$5.29BFY 2025

FY22 —FY23 $4.73BFY24 $4.96BFY25 $5.29B

Total Debt

+2.7% YoY

$1.16BFY 2025

FY22 —FY23 $1.21BFY24 $1.13BFY25 $1.16B

Op. Cash Flow

+49.4% YoY

$470.5MFY 2025

FY22 $-38.4MFY23 $221.7MFY24 $315.0MFY25 $470.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$6.32B +6.0%	$5.97B +10.3%	$5.41B +5.5%	$5.13B	—
Net Income	$135.8M -35.4%	$210.3M +290.2%	$53.9M -71.5%	$188.9M	—
EPS (Diluted)	$0.96 -39.2%	$1.58 +267.4%	$0.43 -71.3%	$1.50	—
Total Assets	$5.29B +6.7%	$4.96B +4.7%	$4.73B	—	—
Total Debt	$1.16B +2.7%	$1.13B -6.0%	$1.21B	—	—
Operating Cash Flow	$470.5M +49.4%	$315.0M +42.1%	$221.7M +678.0%	$-38.4M	—

AI Insight: ARDT Financial Trends

Revenue has grown ~10% year-over-year but a Q3 2025 net loss and persistently negative Q1 operating cash flows signal recurring seasonal cash-burn pressure.

• Revenue rose from $1,450M in Q3 2024 to $1,645M in Q2 2025, a ~13% increase over three quarters.

• Equity strengthened from $740M in Q2 2024 to $1,337M in Q1 2026, nearly doubling over seven quarters.

• Net income turned negative at -$23M in Q3 2025, the only loss quarter in the observed period.

• Total debt held relatively flat, rising modestly from $1,103M in Q2 2024 to $1,163M in Q1 2026.

⚠ Operating cash flow was -$25M in Q1 2025 and -$60M in Q1 2026, suggesting a recurring Q1 cash-drain pattern.

⚠ Q1 2026 revenue of $1,602M is essentially flat versus Q4 2025's $1,605M — watch for re-acceleration.

⚠ Operating income data is absent across all periods, obscuring true underlying profitability trends.

AI Insight: ARDT Ratio Trends

Leverage is steadily unwinding — D/E fell from 1.49 in Q2 2024 to 0.86 in Q1 2026 — but profitability remains volatile and thin outside of one-off quarters.

• D/E ratio declined consistently from 1.49 in Q2 2024 to 0.86 in Q1 2026, marking meaningful balance-sheet deleveraging.

• Operating margin swung from -0.1% in Q3 2025 to 5.8% in Q4 2025 and 4.7% in Q1 2026, signaling persistent volatility.

• Q4 2024 stands out with 10.4% operating margin and 29.5% ROIC — likely a one-time event distorting the trend.

• TTM ROIC of 11.5% and ROE of 10.0% remain modest, reflecting structurally thin healthcare operating margins.

⚠ Q3 2025 posted -0.1% operating margin and -7.6% ROE — a sharp one-quarter deterioration worth monitoring for recurrence.

⚠ ROE and ROIC dipped sequentially from Q2 2025 into Q3 2025 and have not fully recovered to Q2 2025 levels by Q1 2026.

⚠ Continued D/E compression toward or below 0.80 could signal improved financial flexibility and lower refinancing risk.

Get alerted when ARDT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Ardent Health, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ARDT

CHAI TRUST CO LLC
$661.2M77,246,499 sh
Ventas, Inc.
$80.0M9,342,501 sh
GOLDENTREE ASSET MANAGEMENT LP
$19.7M2,303,113 sh
AMERIPRISE FINANCIAL INC
$15.2M1,776,726 sh
BlackRock, Inc.
$15.1M1,758,215 sh
CastleKnight Management LP
$9.2M1,076,967 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.6M1,008,438 sh
AQR CAPITAL MANAGEMENT LLC
$8.1M942,353 sh
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$8.0M930,668 sh
ExodusPoint Capital Management, LP
$5.6M657,903 sh

Fund	Value	Shares
CHAI TRUST CO LLC	$661.2M	77,246,499
Ventas, Inc.	$80.0M	9,342,501
GOLDENTREE ASSET MANAGEMENT LP	$19.7M	2,303,113
AMERIPRISE FINANCIAL INC	$15.2M	1,776,726
BlackRock, Inc.	$15.1M	1,758,215
CastleKnight Management LP	$9.2M	1,076,967
VANGUARD CAPITAL MANAGEMENT LLC	$8.6M	1,008,438
AQR CAPITAL MANAGEMENT LLC	$8.1M	942,353
BRIDGEWAY CAPITAL MANAGEMENT, LLC	$8.0M	930,668
ExodusPoint Capital Management, LP	$5.6M	657,903

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ARDT on your watchlist

Track score changes the day Ardent Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ARDT a good stock to buy?

13F Pro's AI-powered analysis of Ardent Health, Inc. (ARDT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARDT are available on the ARDT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ARDT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARDT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ardent Health, Inc.'s investment landscape.